Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | IL-16 | 18.0 | 35 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 3 | IL-16 | 18.0 | 35 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | IL-16 | 100.0 | 41 | |
N2759 | Poly(I:C) | 2 | ug/mL | 3 | IL-16 | 77.0 | 43 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | IL-16 | 19.0 | 37 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 3 | IL-16 | 25.0 | 52 | ||||
N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | IL-16 | 75.0 | 57 | |
N2586 | Poly(I:C) | 2 | ug/mL | 3 | IL-16 | 65.0 | 55 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 27.5 | 38 | |
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 26.0 | 61 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 51.0 | 49 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 64.5 | 56 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 26.0 | 64 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 27.0 | 53 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 35.0 | 62 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 50.0 | 54 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 31.0 | 46 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 32.0 | 54 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 100.0 | 37 | |
N2759 | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 91.5 | 42 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 57.0 | 41 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 43.0 | 44 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 113.5 | 48 | |
N2586 | IL-1 alpha | 100 | ng/mL | 3 | IL-16 | 101.0 | 39 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IL-16 | 18.0 | 30 |